Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease Overview
Learn About Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease
Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
Friedemann Paul practices in Goyang, Republic of Korea. Paul is rated as an Elite expert by MediFind in the treatment of Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease. Their top areas of expertise are Multiple Sclerosis (MS), Transverse Myelitis, Optic Neuritis, and Neuromyelitis Optica.
John Chen is a primary care provider, practicing in General Practice in Camp Pendleton, California. Dr. Chen is rated as an Elite provider by MediFind in the treatment of Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease. His top areas of expertise are Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease, Increased Intracranial Pressure, Pseudotumor Cerebri Syndrome, Neuromyelitis Optica, and Stent Placement.
Mayo Clinic
Sean Pittock is a Neurologist in Rochester, Minnesota. Dr. Pittock is rated as an Elite provider by MediFind in the treatment of Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease. His top areas of expertise are Optic Neuritis, Transverse Myelitis, Neuromyelitis Optica, and Encephalitis. Dr. Pittock is currently accepting new patients.
Summary: The MESO7 study is a prospective observational research project designed to investigate the mechanisms of resilience and neurodegeneration in neurological diseases and healthy aging. It leverages advanced multiparametric brain and spinal cord imaging at high (3T) and ultra-high magnetic fields (7T) to assess structural, functional, metabolic, and mesoscale changes in the central nervous system (CN...
Summary: The main objective of this study is to evaluate the efficacy of satralizumab compared with placebo based on time from randomization to the first occurrence of an adjudicated MOGAD relapse in the double-blind (DB) treatment period. Participants who experience an adjudicated relapse or complete the DB period can enter open-label extension (OLE) period. After the primary clinical cutoff date (CCOD), ...